Key biomarkers identified for predicting disability progression in multiple sclerosis
A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple sclerosis (MS). The breakthrough research has the potential to transform treatment strategies for millions of MS patients worldwide,
Sanofi’s Multiple Sclerosis Drug Slows Disease’s Progression
Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.
Sanofi’s eyes approval after MS therapy slows disease progression by 31%
After missing primary endpoints in relapsing forms of MS, tolebrutinib has proved its efficacy in secondary progressive MS patients.
Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows
Sanofi SA (NASDAQ:SNY) released data from the HERCULES phase 3 study of tolebrutinib for non-relapsing secondary progressive multiple sclerosis (nrSPMS). The data demonstrated that tolebrutinib delayed the time to onset of 6-month confirmed disability progression (CDP) by 31% compared to placebo (HR 0.
Some people with MS may need earlier, higher-dose meds, study shows
Early, aggressive treatment of brain lesions caused by multiple sclerosis could help ward off faster decline in patients, a ...
News Medical on MSN3d
Therapeutic inertia in the treatment of women with multiple sclerosis revealed
A study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), highlighting gender disparities that could impact long-term health outcomes for women of ...
Rutgers University6d
Testing a Revolutionary Treatment Against Progressive Multiple Sclerosis
Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an ...
Cancer patients benefiting from hair-loss treatment
The catering manager for a local secondary school explained that making the decision to receive cold cap treatment was one of ...
Multiple Sclerosis News Today5d
‘Eating Well with MS’ program improves dietary behavior: Study
The online program "Eating Well with MS" improved dietary behavior among multiple sclerosis patients and was deemed valuable, ...
Medscape9d
Does Multiple Sclerosis Protect Against Alzheimer's?
Patients with MS showed half the rate of amyloid pathology compared with people without MS, suggesting a possible protective ...
Early treatment significantly reduces long-term disability in children with multiple sclerosis, new study finds
New research presented today at European Committee for Treatment and Research in Multiple Sclerosis 2024 reveals that ...
Multiple Sclerosis News Today4d
ECTRIMS 2024: Mavenclad sustains benefits in relapsing MS
A short course of Mavenclad can provide long-term reductions in disease activity and disability progression in highly active ...
BioTechniques2d
Biomarkers for predicting multiple sclerosis progression identified
Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...
Crain's Cleveland Business2d
Cleveland Clinic researcher advises Sanofi on multiple sclerosis drug that slows disease’s progression
Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...